Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders.

Learn more about Xenon Pharmaceuticals, committed to enhancing the lives of patients with neurological disorders through innovative therapeutics.

Xenon is focused on advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Our lead molecule, azetukalner, is a novel, potent …

Dec 6, 2024 · Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com. Safe Harbor Statement

Jan 13, 2025 · [email protected] "Xenon" and the Xenon logo are trademarks of Xenon Pharmaceuticals Inc. They are registered in the United States and used or registered in …

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner. 2

Xenon® and the Xenon logo are registered trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and the European Union. © 2024 Xenon Pharmaceuticals Inc. All rights reserved.

"Xenon" and the Xenon logo are trademarks of Xenon Pharmaceuticals Inc. They are registered in the United States and used or registered in various other jurisdictions. Copyright © 2001 – …

View peer-reviewed journals, company posters, presentations, and other select Xenon publications.

[email protected] "Xenon" and the Xenon logo are trademarks of Xenon Pharmaceuticals Inc. They are registered in the United States and used or registered in various other jurisdictions.